Wells Fargo & Company assumed coverage on shares of Becton, Dickinson and Company (NYSE:BDX) in a report issued on Friday, Marketbeat.com reports. The firm issued an outperform rating and a $225.00 target price on the medical instruments supplier’s stock.

Other equities analysts also recently issued reports about the company. Barclays PLC reaffirmed an equal weight rating and issued a $210.00 price objective (up from $205.00) on shares of Becton, Dickinson and in a research note on Thursday, August 10th. BidaskClub downgraded Becton, Dickinson and from a strong-buy rating to a buy rating in a research note on Monday, July 31st. Piper Jaffray Companies reaffirmed a buy rating and issued a $213.00 price objective on shares of Becton, Dickinson and in a research note on Tuesday, September 12th. Stifel Nicolaus reaffirmed a buy rating on shares of Becton, Dickinson and in a research note on Wednesday, August 9th. Finally, Zacks Investment Research downgraded Becton, Dickinson and from a buy rating to a hold rating in a research note on Monday, August 7th. Five analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. Becton, Dickinson and has an average rating of Buy and an average target price of $200.93.

Shares of Becton, Dickinson and (NYSE BDX) opened at 193.27 on Friday. Becton, Dickinson and has a 12 month low of $161.29 and a 12 month high of $206.63. The stock has a market capitalization of $41.03 billion, a PE ratio of 43.04 and a beta of 1.06. The company’s 50 day moving average price is $199.01 and its 200 day moving average price is $191.58.

Becton, Dickinson and (NYSE:BDX) last released its quarterly earnings data on Thursday, August 3rd. The medical instruments supplier reported $2.46 earnings per share for the quarter, beating the consensus estimate of $2.44 by $0.02. Becton, Dickinson and had a return on equity of 22.53% and a net margin of 6.25%. The firm had revenue of $3.04 billion during the quarter, compared to the consensus estimate of $3.06 billion. During the same period last year, the business posted $2.35 EPS. Becton, Dickinson and’s quarterly revenue was down 5.1% on a year-over-year basis. Equities analysts anticipate that Becton, Dickinson and will post $9.46 earnings per share for the current fiscal year.

WARNING: “Becton, Dickinson and Company (BDX) Earns Outperform Rating from Analysts at Wells Fargo & Company” was originally reported by Daily Political and is owned by of Daily Political. If you are viewing this piece on another site, it was copied illegally and republished in violation of US & international copyright & trademark law. The correct version of this piece can be accessed at https://www.dailypolitical.com/2017/09/26/becton-dickinson-and-company-bdx-earns-outperform-rating-from-analysts-at-wells-fargo-company.html.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 29th. Stockholders of record on Friday, September 8th will be given a $0.73 dividend. This represents a $2.92 dividend on an annualized basis and a dividend yield of 1.51%. The ex-dividend date of this dividend is Thursday, September 7th. Becton, Dickinson and’s dividend payout ratio is currently 83.43%.

In other news, insider Gary M. Cohen sold 15,512 shares of Becton, Dickinson and stock in a transaction on Monday, September 11th. The stock was sold at an average price of $203.77, for a total value of $3,160,880.24. Following the completion of the sale, the insider now owns 95,781 shares of the company’s stock, valued at $19,517,294.37. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Linda M. Tharby sold 4,695 shares of Becton, Dickinson and stock in a transaction on Tuesday, August 22nd. The shares were sold at an average price of $200.48, for a total value of $941,253.60. Following the completion of the sale, the executive vice president now directly owns 18,670 shares of the company’s stock, valued at approximately $3,742,961.60. The disclosure for this sale can be found here. In the last ninety days, insiders sold 75,904 shares of company stock valued at $15,242,688. Company insiders own 1.40% of the company’s stock.

Several large investors have recently made changes to their positions in the company. Vanguard Group Inc. grew its position in shares of Becton, Dickinson and by 8.5% in the second quarter. Vanguard Group Inc. now owns 17,255,948 shares of the medical instruments supplier’s stock valued at $3,366,809,000 after purchasing an additional 1,353,780 shares during the period. BlackRock Inc. grew its position in shares of Becton, Dickinson and by 2,427.8% in the first quarter. BlackRock Inc. now owns 16,542,028 shares of the medical instruments supplier’s stock valued at $3,034,470,000 after purchasing an additional 15,887,611 shares during the period. State Street Corp grew its position in shares of Becton, Dickinson and by 3.5% in the second quarter. State Street Corp now owns 10,270,221 shares of the medical instruments supplier’s stock valued at $2,003,834,000 after purchasing an additional 342,873 shares during the period. JPMorgan Chase & Co. grew its position in shares of Becton, Dickinson and by 6.5% in the first quarter. JPMorgan Chase & Co. now owns 3,967,843 shares of the medical instruments supplier’s stock valued at $727,863,000 after purchasing an additional 242,081 shares during the period. Finally, Northern Trust Corp grew its position in shares of Becton, Dickinson and by 4.0% in the second quarter. Northern Trust Corp now owns 2,813,937 shares of the medical instruments supplier’s stock valued at $549,028,000 after purchasing an additional 106,966 shares during the period. 87.12% of the stock is owned by institutional investors and hedge funds.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Analyst Recommendations for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.